View Item 

Show simple item record

SYMPATHETIC OVERACTIVITY AND CORONARY RISK IN HYPERTENSION

dc.contributor.authorAmerena, Johnen_US
dc.contributor.authorJulius, Stevoen_US
dc.date.accessioned2010-06-01T21:32:35Z
dc.date.available2010-06-01T21:32:35Z
dc.date.issued1997-12en_US
dc.identifier.citationAmerena, John; Julius, Stevo (1997). "SYMPATHETIC OVERACTIVITY AND CORONARY RISK IN HYPERTENSION." Fundamental & Clinical Pharmacology 11(S1): 78s-81s. <http://hdl.handle.net/2027.42/74596>en_US
dc.identifier.issn0767-3981en_US
dc.identifier.issn1472-8206en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74596
dc.format.extent288266 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights1997 SociÉtÉ FranÇaise de Pharmacologie et de ThÉrapeutiqueen_US
dc.titleSYMPATHETIC OVERACTIVITY AND CORONARY RISK IN HYPERTENSIONen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, 3918 Taubman center 48109–0356, Ann Arbor, MI, USAen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74596/1/j.1472-8206.1997.tb00882.x.pdf
dc.identifier.doi10.1111/j.1472-8206.1997.tb00882.xen_US
dc.identifier.sourceFundamental & Clinical Pharmacologyen_US
dc.identifier.citedreferenceJulius S, Jamerson K: Sympathetics, insulin resistance and coronary risk in hypertension: the ‘chicken-and-egg’ question. J Hypertens 1994; 12: 495 – 502.en_US
dc.identifier.citedreferenceAmerena J and Julius S. The rRole of the Autonomic Nervous System in Hypertension. Hypertens Res 1995 18: 2 99 – 110.en_US
dc.identifier.citedreferenceJulius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K. The association of borderline hypertension with target organ changes and higher coronary risk. The Tecumseh Blood Pressure Study. JAMA 1990 264 ( 3 ) 354 – 358.en_US
dc.identifier.citedreferenceFerrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S: Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350 – 357.en_US
dc.identifier.citedreferencePyorala K, Savolainen E, Kaukola S, Haapakoski J: Plasma insulin as a coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2 year follow-up of the Helsinki Policemen Study population. Acta Med Scand Suppl 1985; 701: 38 – 52.en_US
dc.identifier.citedreferenceJamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO: Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993; 21 ( 5 ): 618 – 623.en_US
dc.identifier.citedreferenceStout RW, Bierman EL, Ross R: Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res 1975; 36: 319 – 327.en_US
dc.identifier.citedreferenceGreene AS, Tonellato PJ, Lui J, Lombard JH, Cowley AW, Jr. Microvascular rarefaction and tissue vascular resistance in hypertension. Am J Physiol 1989; 256: H126 – H131.en_US
dc.identifier.citedreferenceDeibert DC, DeFronzo RA: Epinephrine-induced insulin resistance in man. J Clin Invest 1980; 65: 717 – 721.en_US
dc.identifier.citedreferenceZeman RJ, Ludemann R, Easton TG, Etlinger JD: Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta-2-receptor agonist. Am J Physiol 1988; 254: E726 – E732.en_US
dc.identifier.citedreferenceJulius S, Pascual AV, Abbrecht P, London R: Effect of beta-adrenergic blockade on plasma volume in human subjects. Proc Soc Exp Biol Med 1972; 140: 982 – 985.en_US
dc.identifier.citedreferenceCohn JN: Relationship of plasma volume changes to resistance and capacitance vessel effects of sympathomimetic amines and angiotensin in man. Clin Sci 1966; 30: 267 – 278.en_US
dc.identifier.citedreferenceSmith S, Julius S, Jamerson K, Amerena J and Schork N. Hematacrit levels and physiologic factors in Tecumseh, Michigan. J Hypertens 1994; 12: 4 455 – 461.en_US
dc.identifier.citedreferenceKjeldsen SE, Gjesdal K, Eide I, Aakesson I, Amundsen R, Foss OP, Leren P: Increased beta-thromboglobulin in essential hypertension: Interactions between arterial plasma adrenaline, platelet function and blood lipids. Acta Med Scand 1983; 213: 369 – 373.en_US
dc.identifier.citedreferenceJulius S, Pascual AV, London R: Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation 1971; 44: 413 – 418.en_US
dc.identifier.citedreferenceSimpson P: Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha-1 adrenergic response. J Clin Invest 1983; 72: 732 – 738.en_US
dc.identifier.citedreferenceSchelling P, Fischer H, Gantlen D: Angiotensin and cell growth: a link to cardiac hypertrophy? J Hypertens 1991; 9: 3 – 15.en_US
dc.identifier.citedreferenceKannel WB, Gordon T, Castelli WP, Margolis JR: Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med 1970; 72: 813 – 822.en_US
dc.identifier.citedreferenceEgan B, Panis R, Hinderliter A, Schork N, Julius S: Mechanism of increased alpha-adrenergic vasoconstriction in human essential hypertension. J Clin Invest 1987; 80: 812 – 817.en_US
dc.identifier.citedreferenceBrush JE, Cannon RO, Schenke WH, Bonow R, Leon M, Maron B, Epstein S: Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 1988; 319 ( 20 ): 1302 – 1307.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1472-8206.1997.tb00882.x.pdf
Size:
281.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.